Abbott Laboratories (ABT), (founding name: Abbott Alkaloid Company) is a global pharmaceutical company with around 73,000 employees in 150 countries. Abbott was founded in 1888 by Wallace C. Abbott (1857-1921) and is headquartered in Abbott Park, a northern suburb of Chicago, Illinois.
According to Abbott Laboratories's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 23.5789. At the end of 2021 the company had a P/E ratio of 35.2.
Year | P/E ratio | Change |
---|---|---|
2021 | 35.2 | -18.34% |
2020 | 43.1 | 3.71% |
2019 | 41.6 | -22.4% |
2018 | 53.6 | -74.09% |
2017 | 207 | 412.58% |
2016 | 40.4 | 167.34% |
2015 | 15.1 | -49.14% |
2014 | 29.7 | 28.56% |
2013 | 23.1 |
Company | P/E ratio | P/E ratio differencediff. | Country |
---|---|---|---|
![]() Johnson & Johnson JNJ | 22.7 | -3.78% | ๐บ๐ธ USA |
![]() Novartis NVS | 28.8 | 22.30% | ๐จ๐ญ Switzerland |
![]() Pfizer PFE | 7.28 | -69.13% | ๐บ๐ธ USA |
![]() Medtronic MDT | 26.4 | 11.94% | ๐ฎ๐ช Ireland |
![]() Thermo Fisher Scientific TMO | 32.5 | 37.65% | ๐บ๐ธ USA |
![]() Boston Scientific BSX | 111 | 371.23% | ๐บ๐ธ USA |
![]() Hologic HOLX | 20.4 | -13.30% | ๐บ๐ธ USA |
![]() Bristol-Myers Squibb BMY | 25.5 | 8.06% | ๐บ๐ธ USA |
![]() AstraZeneca AZN | 65.5 | 177.71% | ๐ฌ๐ง UK |
![]() GlaxoSmithKline GSK | 4.50 | -80.93% | ๐ฌ๐ง UK |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.